The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study

BMC Cancer

Table 2 Univariate analysis of disease-free survival (DFS) and overall survival (OS) of all patients

Characteristic		Patients (n)	5-yr DFS rate (%)	P	5-yr OS rate (%)	P
Age	<35 yrs	226	79.3	<0.001	86.3	<0.001
	≥35 yrs	2690	88.2		93.1
pT	T1	1763	91.9	<0.001	95.1	<0.001
	≥T2	1147	81		89.2
	Unknown	6
pN	Negative	1685	93.8	<0.001	95.9	<0.001
	Positive	1191	81.4		89.6
	Unknown	40
M	0	2860			93.9	<0.001
	1	56			24.6
Stage	I	1209	95.2	<0.001	97.2	<0.001
	II	1292	89.4		94.8
	III	351	69.2		80.4
	IV	56			24.6
	Unknown	8
HG	1 or 2	1513	88.7	0.39	93	0.84
	3	1191	86.8		92.7
	Unknown	212
ER	Positive	1900	91.1	<0.001	95.7	<0.001
	Negative	1016	80.6		86.8
PgR	Positive	1479	92.4	<0.001	96.6	<0.001
	Negative	1437	82.7		88.7
HER2	Negative	1665	86.1	<0.001	91.4	0.001
	Positive	542	78.4		88.3
	Unknown*	709
Subtype	Luminal A (LA)	1162	89.3	<0.001	93.9	<0.001
	Non-LA	1045	78.5		87.1
	Unknown	709
Histological type	ILC	83	91.7	0.31	93.6	0.38
	IDC	2833	87.4		92.5
p53	0 or 1+	2220	90.9	<0.001	95.2	<0.001
	2+ or 3+	621	81.8		87.1
	Unknown	65
Ki-67	≤20%	1902	90.1	<0.001	94.4	<0.001
	>20%	700	83.4		89.1
	Unknown	314
Operation	BCS	2166	89.5	<0.001	94.6	<0.001
	Mastectomy	724	84.2		88.6
	None	27
Adjuvant therapy
Chemotherapy	Yes	2318	87.7	0.38	92.6	0.87
	No	556	86.6		92.5
Hormone therapy	Yes	2192	90.4	<0.001	95.6	<0.001
	No	724	78.9		83.9
Anti-HER2 therapy	Yes in HER2-positive ^†	147	80.7	0.77	93.1	0.48
	No in HER2-positive	395	77.4		86.9
	HER2-negative or unknown ^§	2374
Radiotherapy	Yes	2387	87.8	0.4	92.3	0.38
	No	529	86.3		92.9

* Including 2+ for HER2 by immunohistochemistry without FISH.
† Thirty-seven of these patients were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial [25] and 53 patients were enrolled in the Tykerb Evaluation After Chemotherapy (TEACH) trial [26].
§ No anti-HER2 therapy due to negative or unknown for HER2 by immunohistochemistry without FISH.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; M, distant metastasis at diagnosis; pT, pathological tumor stage; pN, pathological nodal stage; PgR, progesterone receptor.

ISSN: 1471-2407